Form 4: Amphastar Pharmaceuticals Executives Exercise Stock Options and Sell Shares to Cover Taxes

Jack Y. Zhang and Mary Z. Luo, key executives at Amphastar Pharmaceuticals, exercised stock options and sold shares to cover associated tax liabilities.

Summary

• Jack Y. Zhang, CEO & Chief Scientific Officer, and Mary Z. Luo, COO, Chief Scientist & Chairman, both filed Form 4 documents detailing changes in their beneficial ownership of Amphastar Pharmaceuticals, Inc. stock.
• Both executives exercised employee stock options at a price of $12.46 per share on March 15, 2024.
• They then disposed of shares to cover the exercise price and withholding taxes related to the option exercise and vesting of restricted stock units (RSUs).
• Zhang disposed of 408,721 shares at $43.05 on March 15, 2024, and an additional 15,768 shares at the same price on March 17, 2024, to cover these liabilities.
• Luo disposed of 202,658 shares at $43.05 on March 15, 2024, and 7,052 shares at the same price on March 17, 2024, for the same purpose.
• Following these transactions, Zhang directly owns 2,433,554 shares and indirectly owns 1,229,756 shares, while Luo indirectly owns 6,827,679 shares.
• The indirect ownership is primarily through Mary Z. Luo's holdings and Applied Physics & Chemistry Laboratories, Inc., where the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners.

Sentiment

Score: 5

Explanation: This is a neutral event. Executives exercising options and selling shares to cover taxes is a common practice and doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to track executive sentiment and potential alignment with shareholder interests. These filings are common in the pharmaceutical industry.

Comparison to Industry Standards

• Executive compensation packages often include stock options and RSUs to align management's interests with those of shareholders.
• The exercise of options and subsequent sale of shares to cover taxes is a common practice among executives across various industries.
• Comparable companies such as Teva Pharmaceutical Industries and Mylan (now Viatris) also see similar Form 4 filings from their executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased number of shares in the market.
• The impact on employees is likely minimal, as these are standard executive compensation practices.

Key Dates